Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma

British Journal of Clinical Pharmacology, Supplement

Volumn 52, Issue 3, 2001, Pages 273-278

  Paroni, Rita ^a   Salonia, Andrea ^a   Lev, Avigdor ^b   Da Pozzo, Luigi Filippo ^a   Cighetti, Giuliana ^c   Montorsi, Francesco ^a   Rigatti, Patrizio ^a   Colombo, Renzo ^a  

^a Department of Laboratory Medicine ^*  (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bladder hyperthermia; H.P.L.C; Intravesical chemotherapy; Superficial transitional cell carcinoma; Systemic absorption

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER; BLADDER TUMOR; BLOOD; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG STABILITY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; INTRAVESICAL DRUG ADMINISTRATION; LEUKOCYTE; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TEMPERATURE; TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; TEMPERATURE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0035459198     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01449.x     Document Type: Article

References (24)

1. Torti FM, Lum DL, Aston D. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J Clin Oncol 1987; 5: 125-130.
2. Heney NM, Ahnied S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 136: 1083-1086.
3. Hudson MA, Ratlif TL, Gillen DP, Haaff EO, Dresner SM, Catalona WS. Single course versus maintenance bacillus Calmete-Guerin therapy for superficial bladder tumours: a prospective randomized trial. J Urol 1987; 138: 295-299.
4. Halm GM. Potential for therapy of drugs and hyperthennia. Cancer Res 1979; 39: 2264-2268.
5. Dahl O. Hyperthennia and drugs. In Hyperthermia, eds. Wathmong DJ, Ross WM, Glasgow: Blackie, 1986: 121-153.
6. Herr HW. Intravesical therapy. A critical review. Urol Clin North Am 1987; 14: 399-404.
7. Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with Mytomicin C and local bladder microwave-induced hyperthennia as a preoperative therapy for superficial bladder tumours. A preliminary clinical study. Eur Urol 1991; 20: 204-210.
8. Colombo R, Lev A, Da Pozzo LF, Freschi M, Callus G, Rigatti P. A new approach using local combined microwave hyperthennia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995; 153: 959-963.
9. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy with Mitomycin C as neoadjuvant treatment for selected multifocal and urresectable superficial bladder tumours. Acta Urol Ital 1995; 4: 167-171.
10. Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthennia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996; 155(4): 1227-1232.
11. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumours. J Urol 1998; 159: 783-787.
12. Leib Z, Daniel J, Servadio C, et al. Mytomicin C (MMC) vs MMC combined with local microwave hyperthennia (LMWH) as prophylaxis of recurrence of superficial transitional bladder cancer: a preliminary report. Eur Urol 1996; 30: 198.
13. Colombo R, Brausi M, Da Pozzo LF, et al. Thermo-chemotherapy and electromotive drug administration of Mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur Urol 2001; 39: 95-100.
14. Aeikens B, Niermann R, Schindler E. Investigation about the penetration depth in the normal bladder wall and tumour by local instillation of Mitomycin into the urinary bladder. Urol Int 1982; 37: 389-393.
15. den Hartigh J, McVie JG, van Oort WJ, Pinedo HM. Phamiacokinetics of Mitomycin C in humans. Cancer Res 1983; 43: 5017-5021.
16. Wientjes MG, Dalton JT, Badalament RA, Dasani BM, Drago JR, Au JL-S. A method to study drug concentration-depth profiles in tissues: Mitomycin C in dog bladder wall. Pliartn Res 1991; 8: 168-173.
17. Dalton JT, Wientjes MG, Badalament RA, Drago JR, An JL-S. Phanmcokinetics of intravesical Mitomycin C in superficial bladder cancer patients. Cancer Res 1991; 51: 5144-5152.
18. Schillingen TD, An JL-S, Wientjes MG, Badalament RA. Pharmacodynaniics of Mitomycin C in cultured human bladder tumours. Cancer Res 1991; 51: 3849-3856.
19. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL-S. Bladder wall penetration of intravesical Mitomycin C in dogs. Cancer Res 1991; 51: 4347-3454.
20. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S. Penetration of Mytomicin C in human bladder. Cancer Res 1993; 53: 3314-3320.
21. Gao X, Au JL-S, Badalament RA, Wientjes MG. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res 1998; 3(1): 139-143.
22. Crooke ST, Henderson M, Samson M, Baker LH. Phase I study of oral Mitomycin C. Cancer Treat Rep 1976; 60: 1633-1636.
23. Paroni R, Arcelloni C, De Vecchi E, Fenno I, Mauri D, Colombo R. Plasma Mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Clin Client 1997; 43: 615-618.
24. Dewhirst HW, Sim DA, Gross J, Kundrat MA. Effect of heating rate in tumour and normal tissue microcirculatory function. In Hyperthennic Oncology, Vol. 1, eds. Overgaard J, London, Philadelphia: Taylor & Francis, 1984: 77-180.